However, when we analyzed a public data set of CLL cells from 7 patients with persistent MRD after 1 year on venetoclax-based therapy (RNA-Seq GSE192685 (40)), we found that 5 out of 7 CLL samples showed higher SPHK2 expression at progression on venetoclax therapy (SC2) compared to the values prior to venetoclax treatment (SC1) (Supplementary 7). The gene discussed is SPHK2; the disease is B-cell chronic lymphocytic leukemia.